Csl Limited · ASX:CSL
Csl — Shareholder Meeting (October 2004)
21 slides from Csl's shareholder meeting presentation, Oct 14, 2004
Slide 1: Chairman's Address and Managing Director's Presentation
14 October 2004 The Company Announcements Office Australian Stock Exchange Limited 530 Collins St MELBOURNE VIC 3000 Dear Sir/Madam CHAIRMAN’S ADDRESS AND MANAGING DIRECTOR’S PRESENTATION Please find attached copies of the Chairman’s Address and Managing Director’s presentation slides to be presente
Slide 2: Chairman's Address, Annual General Meeting
CSL LIMITED CHAIRMAN’S ADDRESS ANNUAL GENERAL MEETING 14 OCTOBER 2004 “This has been a milestone year for CSL with a major acquisition that has considerably strengthened our global plasma therapeutics business and positioned the company for substantial and profitable future growth. “In March 2004, C
Slide 3: ZLB Behring and Plasma Services
* Wound treatment therapies used to minimise blood loss; and *® Treatment for pulmonary disease. “Based at King of Prussia in Pennsylvania, ZB Behring is one of the world’s leading manufacturers of plasma therapeutics with substantial markets in the US, Europe and Japan. ZLB Behring operates regiona
Slide 4: Vaccines and Pharmaceutical business
“In June 2004, the Federal Government announced plans for free vaccination against pneumococcal infection for people aged over 65. Due to commence in January 2005, this program will lead to increased sales of Pneumovax 23, a product distributed in Australia by CSL on behalf of Merck & Co. Ine. “CSL
Slide 5: JRH Biosciences growth
“JRH Biosciences has maintained its performance of strong growth with sales revenue increasing 14% to $192.5 million. Growth in all product lines and enhancements to key facilities strengthened JRH’s international position as a leading supplier of media for the biopharmaceutical industry. “Maintaini
Slide 6: New accounting standards and shareholder questions
“Whilst CSL has not fully quantified the impact of these new standards on the financial statements, we do not believe that it will have a material effect on shareholder value or forecast earnings. “The key areas where accounting policies will change and may have an impact on the financial statements
Slide 7: Complex results, discount on acquisition and inventory
“T will be the first to acknowledge that this year’s results are complex and unusual and we have tried to address this issue through much fuller disclosure than is required by the accounting standards. “This has been a year of transformation for CSL. The acquisition of Aventis Behring was made at a
Slide 8: CSL Board
CSL_BOARD “In respect to matters affecting the Board, I and the Board were pleased to be able to announce the appointment of Mr John Akehurst and Mr Maurice Renshaw as Directors who are both offering themselves for election at this meeting. Both candidates offer outstanding credentials and I am pers
Slide 9: IG Ai a i
IG Ai a i
Slide 10: Highlights
Highlights a ‘Record Result - Strong Balance Sheet. NPAT. up 212% Cash flow-up 79% EPS $1.23 Net Debt / Net Debt & Equity 26% m Acquisition of Aventis Behring ¢ Integration.on track... “ecm 70% of milestones complete Sale of Animal Health at HPV-~ Phase Ill «Progressing with FDA filing targetted for
Slide 11: Reported and FX adjusted results
Reported Chg s~FX Adj. Chg ASM ASM Revenues 1,836 = 40% ~=—=s—i« BAH 1% EBITDA. 399 56% ‘445 «475% EBIT 269 99% 303 #124% NPAT (Pre GW) 262 ~ 132% 993 160% “CFO 207 79% AT 89% —pPSCents —«s-38_——s—«i% CSL Limited Annual General Meeting
Slide 12: Net Profit After Tax
SM Net Profit After Tax 300) oo (pre G/Will) 260 . Animal 200 Health 150 50° : I ot . | i 2001.” 2002 ~.4999..- 2000 .-2004.-.2002.-2003 - 2004.°> -EBITA - sm. R&D Spend : 420., : ~ 100 a 2000 2001. 2002... 2003... 2004 419992000 °° 2001 --- 2002 ...2003.-. 2004 - CSL Limited Annual General Meeting
Slide 13: Plasma Therapeutics Industry
Plasma Therapeutics Industry Strategy Global Market Share” _2LB Behring 21% Broad Product Portfolio _ & Continuing Innovation — LowCostHigh Yield / Manufacturing - _CSL 2% Balancing Cash flow& Market Demands Maximising Profitable _ Lites ~~ - Approx. 23% share. -of $US7bn industry : oe Approx. 25% s
Slide 14: Integration milestones
number of milestones ~ 70% of Integration milestones completed « Marburg social plan signed by works council « Commercial Operations consolidated «Vienna shut down, social plan signed by works council «King of Prussia HQ restructuring complete, Glendale office closed °Plasma centres closed, testing
Slide 15: ZLB Behring Pro-forma 2004/2005 Sales Split
_ ZLB Behring Pro-forma 2004/2005 Sales Split Per Therapeutic Category. -.Per Region In. percent of total sales : : in percent of total sales rEVIII : ; 2 North America : Be Pd Coagulation oS HE Western Europe Mi Critical Care oN centel Eurene i 2are : : W9@9 Japan fy Wound Healing ~~ : fag Intercon
Slide 16: Operational Centres of Excellence
Operational Centres of Excellence Plasma _ Fractionation Production. Filling/ : .. Packaging Nain, : me 7 é Haemophilia Critical Care : products ] fare _ imamunes! “3, Wound Healing : : SiG Centre of Excellence - ~ . CSL Limited Annual General Meeting
Slide 17: Total US Plasma Collection Centres
_Total US Plasma Collection Centres Jun 03— Dec 03 Mar04- Jun 04 CSL Limited Annual General Meeting
Slide 18: ZLBB - Market Conditions
_ZLBB - Market Conditions Core Products wi pdFVIII ; 8 Industry managing ongoing transition to recombinants “8 Growing volume of pdF VIII sold into and tier markets « VWF demand growing (Humate P) mIVIG * Prices have been stable with upward pressure going forward ° Currently experiencing solid deman
Slide 19: Product development pipeline
vWD* (Humate P- improved formulation) — immunodeficiency (subcutane usly delivered IgG) _ ITP* (Anti D fone) Le - USA aOR cie es 12% liquid VIG (usa) Homupodeficten andITP*: _ Erromaroaiap? ic Liquid vic Stroke: reconstituted High Density Li protein Hepatitis c veces o> Col aboration — *VWD: von Wil
Slide 20: Strategic Direction
“Strategic Direction Increased focus on Human Health —- Global Scale - Innovation — Financial Discipline — : Great People, Core Values CSL Limited Annual General Meeting
Slide 21: IG Ai a i
IG Ai a i